Parallel Bio

Using the immune system to cure disease

Operating in healthcare based in San Francisco, CA, USA, Parallel Bio operates.

Profile

Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. Using groundbreaking biological and computational tools that track real clinical outcomes, the company generates data that enable earlier, more reliable decisions about disease biology and drug development.

Parallel Bio’s platform overcomes the core limitations of traditional animal testing, which fails to encapsulate the complexity of human biology. The company is building internal pipelines of novel disease targets and drug candidates in both cancer and autoimmune disease, while collaborating with pharmaceutical companies to evaluate therapies directly in human systems to reduce the cost and risk of clinical trials.

Based in San Francisco, the company was founded in 2021 by two of the world’s leading experts in replacing animal models with human-first platforms.

Its activity falls under healthcare; the profile below is assembled from public directory data.

The business is associated with San Francisco, CA, USA.

Its current recorded stage is Summer 2021.

The company reports a headcount in the 20 range.

Website: parallel.bio